Episode Description
Is there still time for investors to join the biotech rally, or have they already missed it? Rod Wong says there is still plenty of opportunity and sits down with Stephanie Sirota to make the case. They start by contrasting high-profile concerns about AI’s risks with Rod’s more measured view: manage the downside, and position early to capture the benefits. He then explains why today’s rally is built on real commercial data and fundamentals rather than the hype around technology platforms in 2020, and why cancer could be the biotech sector’s flag-bearer for the next decade. Rod discusses how FDA leadership is signaling more support for biotech innovation, how an M&A wave is reshaping the sector, and how commercial launches are outperforming expectations. Looking ahead, Rod shares what he’s watching next. He closes with his biggest-picture takeaway: that medicine is entering a golden age of innovation, one that AI’s growing impact on drug discovery productivity will only help accelerate.
Podcast Team
● Producer and Editor: Tim Young
● Cinematography: Peter Garofalo
● Assistant Camera/Swing: Kate Montgomery
● Executive Editorial Advisor: Stephanie Sirota
● Editorial Advisors: Steve Alperin and Jim Heins
● Theme Music: Ganymede by Yehezkel Raz, with additional music by APM Music.
Featuring: Rod Wong, Founder, Managing Partner and Chief Investment Officer at RTW Investments, moderated by Stephanie Sirota, Partner and Chief Business Officer at RTW Investments.
Follow Us
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.
Chapters
00:00 – Introduction
01:10 – AI and the Fate of Humanity
04:13 – Tech vs. Biotech: Value and Villains
06:27 – The RTW Model
09:35 – What's Driving the Recovery Now
12:58 – The Decade of Oncology
15:16 – FDA Leaning into Innovation
18:39 – M&A and the Eli Lilly Effect
21:08 – Launch Performance and Public Markets
24:28 – What's Next
25:21 – Closing Thoughts
Disclaimer
This interview features Rod Wong, Founder, Managing Partner and Chief Investment Officer at RTW Investments, in conversation with Stephanie Sirota, Partner and Chief Business Officer at RTW Investments.
Statements by RTW personnel reflect their own views and opinions as of the date of recording and are subject to change without notice. Nothing in this episode is intended as investment advice, a recommendation to buy or sell any security, or an offer or solicitation to provide investment advisory services. The views expressed are those of the participants and do not necessarily reflect the views of RTW Investments, its affiliates, or its clients. This content is for informational purposes only.
